SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Biotech Files Clinical Trial Applications with SFDA for its Proprietary Pneumococcal Polysaccharides Vaccines (PPV) -Completes Pre-Clinical Studies- Source: Sinovac Biotech Ltd. On Monday January 31, 2011, 8:00 am EST BEIJING, Jan. 31, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq:SVA - News), a leading provider of biopharmaceutical products in China, announced today the submission of the applications to commence human] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China x o Form 20-F SINOVAC BIOTECH LTD.]

By | 2016-03-24T02:03:42+00:00 April 18th, 2011|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[BioStar Pharmaceuticals Inc. Announces Appointment of New Chief Financial Officer; Appoints Audit Committee Chairman and Independent Director to the Board of Directors XIANYANG, China, April 12, 2011 – Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) (“Biostar” or “the Company”), Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules (“Xin Aoxing Capsules”), in addition to a portfolio]

By | 2016-03-03T13:01:31+00:00 April 12th, 2011|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: BioStar Pharmaceuticals Inc. Announces Appointment of New Chief

[BioStar Pharmaceuticals Inc. Announces Appointment of New Chief Financial Officer; Appoints Audit Committee Chairman and Independent Director to the Board of Directors XIANYANG, China, April 12, 2011 – Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) (“Biostar” or “the Company”), Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules (“Xin Aoxing Capsules”), in addition to a portfolio]

By | 2016-03-03T13:02:45+00:00 April 12th, 2011|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[BioStar Pharmaceuticals Announces Appointment of New Chief Financial Officer; Appoints Auditmmittee Chairman and Independent Director to the Board of Directors Finally, thempanyso announced that the Board has appointed Mr. King-fai (Patrick) Leung an independent director to the Board and Chairman of theAuditmmittee to fill vacancies resulting from Mr. Pans departures, discussedove.]

By | 2016-02-07T16:19:12+00:00 April 12th, 2011|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: BioStar Pharmaceuticals Announces Appointment of New Chief Financial

[BioStar Pharmaceuticals Announces Appointment of New Chief Financial Officer; Appoints Auditmmittee Chairman and Independent Director to the Board of Directors Finally, thempanyso announced that the Board has appointed Mr. King-fai (Patrick) Leung an independent director to the Board and Chairman of theAuditmmittee to fill vacancies resulting from Mr. Pans departures, discussedove.]

By | 2016-02-07T16:20:03+00:00 April 12th, 2011|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 10-K: (Original Filing)

[TO ANNUAL REPORT ON FORM 10-K FOR YEAR ENDED DECEMBER 31, 2010 Page 3] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this annual report on Form 10-K of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Michael H. Lan, certify that: 1. I have reviewed this annual report on Form 10-K of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. Weibing Lu Chief Executive Officer April 11, 2011 EX-32.1 6 v218099_ex32-1.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. Michael H. Lan Chief Financial Officer April 11, 2011 EX-32.2 7 v218099_ex32-2.htm]

By | 2016-03-01T05:25:01+00:00 April 11th, 2011|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 10-K: TO ANNUAL REPORT ON FORM 10-K FOR YEAR

[TO ANNUAL REPORT ON FORM 10-K FOR YEAR ENDED DECEMBER 31, 2010 Page 3] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this annual report on Form 10-K of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Michael H. Lan, certify that: 1. I have reviewed this annual report on Form 10-K of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. Weibing Lu Chief Executive Officer April 11, 2011 EX-32.1 6 v218099_ex32-1.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. Michael H. Lan Chief Financial Officer April 11, 2011 EX-32.2 7 v218099_ex32-2.htm]

By | 2016-03-01T05:25:50+00:00 April 11th, 2011|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL] 10-K: TO ANNUAL REPORT ON FORM 10-K FOR YEAR

[TO ANNUAL REPORT ON FORM 10-K FOR YEAR ENDED DECEMBER 31, 2010 Page 3 PART I Item 1. Business 3 Item 2. Properties 13 Item 3. Legal Proceedings 14 PART II 16 Item 5. 16 Item 7. Managements Discussion and Analysis of Financialnditions and Results of Operations 17 Item 8.] [SECTION 302 OF THERBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this annual report on Form 10-K ofystar Bio-Pharmaceuticalmpany; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [SECTION 302 OF THERBANES-OXLEY ACT OF 2002 I, Michael H. Lan, certify that: 1. I have reviewed this annual report on Form 10-K ofystar Bio-Pharmaceuticalmpany; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and result of operations of thempany at thetes and for the periods indicated. Weibing Lu Chief Executive Officer April 11, 2011] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and result of operations of thempany at thetes and for the periods indicated. Michael H. Lan Chief Financial Officer April 11, 2011]

By | 2016-02-05T03:44:16+00:00 April 11th, 2011|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL] 10-K: (Original Filing)

[TO ANNUAL REPORT ON FORM 10-K FOR YEAR ENDED DECEMBER 31, 2010 Page 3 PART I Item 1. Business 3 Item 2. Properties 13 Item 3. Legal Proceedings 14 PART II 16 Item 5. 16 Item 7. Managements Discussion and Analysis of Financialnditions and Results of Operations 17 Item 8.] [SECTION 302 OF THERBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this annual report on Form 10-K ofystar Bio-Pharmaceuticalmpany; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [SECTION 302 OF THERBANES-OXLEY ACT OF 2002 I, Michael H. Lan, certify that: 1. I have reviewed this annual report on Form 10-K ofystar Bio-Pharmaceuticalmpany; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and result of operations of thempany at thetes and for the periods indicated. Weibing Lu Chief Executive Officer April 11, 2011] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and result of operations of thempany at thetes and for the periods indicated. Michael H. Lan Chief Financial Officer April 11, 2011]

By | 2016-02-05T03:43:27+00:00 April 11th, 2011|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] SC 13G/A: (Original Filing)

[reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the liabilities of]

By | 2016-03-03T13:04:05+00:00 April 4th, 2011|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments
Skip to toolbar